抗粉体剂:一个自我实现的预言
Alexandros Giannakis1, Spiridon Konitsiotis1
1Department of Neurology, University of Ioannina, University Campus, Stavrou Niarchou Av., Ioannina, Greece.
概括
阿尔茨海默病 (AD) 针对β粉样蛋白的治疗是无效的,因为AD比最初定义的更复杂. 将AD重新定义为多因素性疾病对于有效的神经退行性疾病治疗至关重要.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
背景情况:
- 最近的阿尔茨海默氏病 (AD) 诊断标准以粉样β为中心,与抗粉样抗体疗法保持一致.
- 尽管如此,粉样蛋白向治疗在临床实践中表现出有限的疗效.
- 这种差异表明,目前对AD的定义可能是不完整的.
研究的目的:
- 调查阿尔茨海默病中粉样蛋白向疗法的有限疗效背后的原因.
- 根据其复杂的多因素性质,提出对阿尔茨海默病的重新定义.
- 突出需要考虑共存的病理和不同的病原遗传机制.
主要方法:
- 审查当前的阿尔茨海默病诊断标准和治疗策略.
- 对被排除在抗粉样抗体试验之外的患者群体的分析.
- 检查超出粉样蛋白积累的新兴病原遗传机制,如神经炎症和脑血管疾病.
主要成果:
- Amyloid 向疗法在患有特定疾病的患者中是无效的,例如 APOE4 同性或使用抗凝剂.
- 神经炎症,脑血管疾病和金属离子失调是重要的贡献因素.
- 阿尔茨海默病的病理常常与其他大脑病理共存,使疾病机制复杂化.
结论:
- 阿尔茨海默病应该重新定义为一种多因素的神经退行性疾病.
- 有效的治疗需要解决多种病原遗传途径,而不仅仅是粉样蛋白积累.
- 未来的治疗策略必须考虑到AD的异质性和复杂性.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
19.4K
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Stereotype Threat and Self-fulfilling Prophecies
37.6K
When we hold a stereotype about a person, we have expectations that he or she will fulfill that stereotype. A self-fulfilling prophecy is an expectation held by a person that alters his or her behavior in a way that tends to make it true. When we hold stereotypes about a person, we tend to treat the person according to our expectations. This treatment can influence the person to act according to our stereotypic expectations, thus confirming our stereotypic beliefs. Research by Rosenthal and...
37.6K
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
